Pharmaceutical composition
OwnerAnees Abdulquadar Karnachi, Simon David Batemaninventors
Life of this patent
Estimating the term…
Abstract
Disclosed herein are tablets and methods of treatment comprising the administration of such tablets. The tablets are immediate release tablets that comprise about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, where the 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof comprises between 60 and 70% by weight of the tablet. The methods involve the administration of the tablets of the invention to individuals in need of administration of such tablets.
Claims85
A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising:
- an immediate release tablet comprising about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, wherein the tablet comprises between about 60% and 70% by weight of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, wherein said immediate release tablet does not comprise sufficient water-insoluble or polymeric components to impart extended release characteristics to said composition.
A composition for treating a cyclooxygenase-2 dependent disorder or condition, the composition comprising:
- (a) an immediate release tablet comprising about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, where the tablet comprises between about 60% and 70% by weight of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof;
- and
- printed instructions directing that the immediate release tablet comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid be administered orally once a day.
A method of treating a cyclooxygenase-2 dependent disorder or condition comprising:
- administering about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof in the form of single, immediate release tablet, where the tablet comprises between about 60% and 70% of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof by weight, orally once a day to a human in need of such treatment, wherein said immediate release tablet does not comprise sufficient water-insoluble or polymeric components to impart extended release characteristics to said composition.
A method of achieving inhibition of cyclooxygenase-2 in a human subject over a period of about 24 hours comprising administering to a subject in need of such treatment a single immediate release tablet comprising a dose of about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which dose is effective for inhibiting cyclooxygenase-2 over a period of about 24 hours without the use of a sustained release formulation.
A method of achieving a prophylactic or therapeutic effect in a cyclooxygenase-2-mediated disorder or condition in a human subject over a period of about 24 hours, which method comprises administering to a subject in need of such treatment a single immediate release tablet comprising a dose of about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which dose is effective over a period of about 24 hours without the use of an extended release formulation.
Dependencies are inferred from the claim text.